Compare Sana Biotechnology Inc (SANA) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wayfair Inc — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: Wayfair Inc is far larger — about 17.2× Sana Biotechnology Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Wayfair Inc for 8 Days on average.
| SANA | W | |
|---|---|---|
Market Cap | $836.71M | $14.40B |
Volume | 4,507,444 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $119.05 |
52-Week Low | $2.68 | $57.40 |
Typical Hold Time | 23 Days | 8 Days |
Enterprise Value | $749.96M | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Wayfair (W) trades at $105.74, up 1.22% today, with bullish technical signals from moving averages and a consensus analyst price target of $114.13. The company maintains strong revenue growth ($12.9B in 2026) but faces profitability challenges with negative net margins (-2.49%). Recent developments include the launch of the 'Wayfair Delivers' brand platform and upcoming Q3 2026 earnings on November 4, 2026.
Investment outlook remains cautiously optimistic given analyst support (54% buy ratings) and positive technical momentum, though persistent unprofitability and high debt-to-asset ratio (95% in 2025) present significant risks. The stock offers upside to price targets if margin improvements materialize, but requires monitoring of cash flow trends and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
